CAPRNasdaqPharmaceutical PreparationsFiscal year ends December 31

CAPRICOR THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$6.65−0.06 (-0.89%)

Close on Oct 19, 2026

Market cap: $385.21M
P/E (TTM): –
Dividend yield: –

CAPRICOR THERAPEUTICS, INC. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Revenue	0	22	25	2.55	0.24	0.31	1.01	1.67	2.67	4.00	5.52	4.79	0.50	0.20	1.35	–	–	–	–	–
Research & Development	84	50	36	22	14	8.46	5.14	12	11	16	14	7.79	5.20	2.63	4.14	4.08	–	–	–	–
General & Administrative	24	15	13	10	7.61	5.54	3.60	4.93	4.76	4.93	4.37	3.02	2.21	1.36	2.12	2.21	–	–	–	–
Operating Expenses	108	65	49	32	21	14	8.74	17	16	21	18	11	7.41	4.00	6.25	6.29	–	–	–	–
Operating Income	-108	-43	-24	-30	-21	-14	-7.73	-15	-13	-17	-13	-6.02	-6.90	-2.10	-4.90	-6.29	–	–	–	–
Interest Expense	3.05	0	–	–	–	–	–	0	0.40	0.34	0.25	0.20	0.06	0	0	–	–	–	–	–
Interest & Investment Income	6.26	2.20	1.73	0.52	0.06	0.03	0.09	0.14	0.04	0.01	0.00	0.00	-0.01	0.03	0.01	0.02	–	–	–	–
Other Non-Operating Income	3.10	2.10	1.79	0.68	0.92	0.03	0.09	0.14	15	-1.83	-0.25	-0.20	-1.99	0.03	0.01	0.26	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	0	–	–	–	–	0	1.92	0	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-0.16	-0.11	-0.01	-0.03	-0.01	0	0.00	0	–	–	–	–	0	0	0.00	–	–	–	–	–
Pretax Income	-105	-40	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	0.00	0.00	–	–	–	–	–	–	–	–	–	–	–	0	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-105	-40	-22	-29	-20	-14	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-105	-40	-22	-29	-20	-14	-7.64	-15	2.43	-19	-13	-6.22	-8.89	-2.07	-1.15	-1.06	-0.15	-0.63	-0.98	-1.17
EPS (Basic)(per share)	-2.26	-1.15	-0.83	-1.18	-0.87	-0.88	-2.06	-5.17	1.00	-10.10	-8.10	-5.30	-8.50	-2.10	-5.53	-8.08	–	–	–	–
EPS (Diluted)(per share)	-2.26	-1.15	-0.83	-1.18	-0.87	-0.88	-2.06	-5.17	0.90	-10.10	-8.10	-5.30	-8.50	-2.10	-5.53	-8.08	–	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	46	35	27	25	23	16	3.71	2.94	2.32	1.86	1.59	1.17	1.05	0.99	0.88	–	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	46	35	27	25	23	16	3.71	2.94	2.68	1.86	1.59	1.17	1.05	0.99	0.88	–	–	–	–	–
EBITDA	-106	-41	-23	-29	-21	-14	-7.56	-15	-13	-17	-13	-5.98	-6.88	-2.08	-4.89	-6.28	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -46.6%

Financial strength

Current ratio: 7.35
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 63.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.56
Dividend yield: –